Holen Sie sich die Stockscreener-App
43.54
1.05%
-0.46
Schlusskurs vom Vortag:
$44.00
Offen:
$44.17
24-Stunden-Volumen:
2.32M
Relative Volume:
0.64
Marktkapitalisierung:
$7.24B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-20.71
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
-2.16%
1M Leistung:
-29.01%
6M Leistung:
-41.78%
1J Leistung:
-36.35%
1-Tages-Spanne:
$43.24
$44.17
1-Wochen-Bereich:
$43.24
$46.95
52-Wochen-Spanne:
$43.01
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
43.54 | 7.40B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
When Will Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Become Profitable? - Moomoo
What Ionis Pharmaceuticals (IONS)'s Phase 3 Wins Mean For Shareholders - Simply Wall Street
Return on invested capital % of Ionis Pharmaceuticals, Inc. – HAN:ISI - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – HAN:ISI - TradingView
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ - Stocktwits
Ionis Pharmaceuticals Inc. (IONS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $85 - Moomoo
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide - Yahoo Finance
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits
Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis - Yahoo Finance
IONS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating on trial data - Investing.com
Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS) - The Globe and Mail
Oppenheimer reiterates Ionis stock rating on late-stage wins By Investing.com - Investing.com Canada
Ionis Pharmaceuticals, Inc. (IONS) Options ChainYahoo Finance - Yahoo! Finance Canada
Otsuka, Ionis notch phase III win in FUS-ALS - BioWorld News
IONIS Pharmaceuticals (NASDAQ: IONS) Announces Positive Interim Phase 3 Data for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Pharmaceuticals and Roche Announce Positive Phase 3 Interim Results for Sefaxersen in IgA Nephropathy - Kalkine Media
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs - Zacks Investment Research
Roche, Ionis RNA drug scores in kidney disease study - BioPharma Dive
IONS Looks 5.2% Undervalued on GF Value™ Amid RNA Therapy Trial News - GuruFocus
Ionis Pharmaceuticals' Phase 3 kidney trial meets proteinuria endpoint - Mugglehead Investment Magazine
Otsuka, Ionis to Discuss Approval Path for FUS-ALS Drug With Regulators - GenomeWeb
Ionis Pharmaceuticals stock hits 52-week low at $44.20 By Investing.com - Investing.com India
Ionis Pharmaceuticals stock hits 52-week low at $44.20 - Investing.com
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease - AOL.com
BMO reiterates Ionis Pharmaceuticals stock rating on ALS drug data By Investing.com - Investing.com Canada
Roche, Ionis post trial win for kidney drug (IONS:NASDAQ) - Seeking Alpha
Form 8K IONIS PHARMACEUTICALS For: 23 September By Investing.com - Investing.com Nigeria
Canaccord reiterates Ionis stock rating on positive trial results By Investing.com - Investing.com Canada
Ionis reports positive Phase 3 interim results for sefaxersen in IgA nephropathy - TradingView
Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen - Yahoo
Otsuka and Ionis report positive Phase III readout for ulefnersen - The Pharma Letter
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - BioSpace
Ionis, Roche report positive phase 3 data for kidney drug - Investing.com
Ionis, Roche report positive phase 3 data for kidney drug By Investing.com - Investing.com Australia
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ionis and Otsuka Report Positive Phase 3 Data for FUS-ALS Drug Ulefnersen - finance.biggo.com
IONS Looks 7.0% Undervalued on GF Value™ - GuruFocus
Ionis to Seek Expedited FDA Review for ALS Drug - Benzinga
IONS Looks 7.2% Undervalued on GF Value™ Amid Mixed Growth and P - GuruFocus
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView
Otsuka, Ionis’ experimental ALS drug meets main goal in late-stage study - 101 WIXX
JPMorgan cuts Ionis Pharmaceuticals stock price target on launch concerns By Investing.com - Investing.com UK
Ionis drug meets primary goal in rare ALS gene mutation trial - Investing.com Canada
Ionis drug meets primary goal in rare ALS gene mutation trial By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile - TradingView
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director |
Jul 31 '26 |
Buy |
51.60 |
5,000 |
258,000 |
24,000 |
| HERMAN JOAN E | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
51,306 |
| BERTHELSEN SPENCER R | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
5,220 |
0 |
161,233 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
85.46 |
15,000 |
1,281,930 |
0 |
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Jul 07 '26 |
Sale |
83.58 |
5,536 |
462,693 |
75,018 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Option Exercise |
47.11 |
10,111 |
476,329 |
13,922 |
| Diaz Allene M. | Director |
Jul 07 '26 |
Sale |
85.42 |
10,111 |
863,637 |
3,811 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer |
Jul 07 '26 |
Sale |
84.30 |
362 |
30,517 |
22,096 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):